SCHAUMBURG, Ill., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT) today announced U.S. FDA approval of its Haloperidol Injection, USP, an antipsychotic medication. Sagent’s haloperidol will be offered in 5 mg per mL single-dose and 50 mg per 10 mL multi-dose, latex-free vials. According to 2011 IMS data, the annual U.S. injectable market for haloperidol approximated $12.5 million. As with all products in Sagent’s portfolio, haloperidol features the company’s reventIV MeasuresSM packaging and labeling designed to aid in the reduction of medication errors. Sagent expects to launch the product early in the fourth quarter.
